Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 P217 | DOI: 10.1530/endoabs.110.P217

ECEESPE2025 Poster Presentations Bone and Mineral Metabolism (112 abstracts)

Histopathological and clinical differences in primary hyperparathyroidism: a retrospective analysis of parathyroid adenomas with severe and mild hypercalcemia

Irem Sonmezoglu Kutuk 1 , Meral Uner 2 , Cenk Sokmensuer 2 , Suleyman Nahit Sendur 3 & Bulent Yildiz 3


1Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye; 2Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Türkiye; 3Division of Endocrinology and Metabolism, Hacettepe University Faculty of Medicine, Ankara, Türkiye


JOINT1337

Background and Aim: Primary hyperparathyroidism (PHPT), predominantly caused by parathyroid adenomas, exhibits a broad spectrum of clinical and histopathological manifestations, ranging from mild to severe hypercalcemia. Severe hypercalcemia (Ca >13 mg/dL) is linked with complications such as osteoporosis and nephrolithiasis, while mild hypercalcemia (Ca <12 mg/dL) is often asymptomatic. This study aimed to explore differences in tumor characteristics, clinical outcomes, and histopathological markers between these groups, providing insights into their pathophysiology and prognostic implications.

Subjects and Methods: A retrospective analysis was conducted on 66 patients with PHPT due to parathyroid adenomas. Patients were divided into two age-matched groups: 46 with mild hypercalcemia (Ca <12 mg/dL; mean age 54. 3 ± 11. 3 years) and 20 with severe hypercalcemia (Ca >13 mg/dL; mean age 51. 9 ± 17. 8 years). Immunohistochemical analyses for parafibromin, cyclin D1, TP53, and Ki67 were performed on pathological specimens. Tumor size, mitotic activity, fibrosis, and clinical, hormonal, and biochemical parameters were also evaluated.

Results: The severe hypercalcemia group demonstrated significantly higher median serum calcium and parathormone levels (13. 8 mg/dL [IQR: 13. 3–14. 5], 351. 4 pg/mL [IQR: 216. 9–487. 7]) compared to the mild hypercalcemia group (11. 2 mg/dL [IQR: 10. 9–11. 6], 152. 3 pg/mL [IQR: 121. 3–227. 6]). Despite these differences, no significant variations were found between the groups in tumor size (P = 0. 43), mitotic activity (P = 1. 0), fibrosis (P = 0. 12), or immunohistochemical markers such as parafibromin (P = 0. 47), cyclin D1 (P = 0. 7), beta-catenin (P = 0. 82), and Ki67 (P = 0. 63). Additionally, there were no significant differences in the prevalence of osteoporosis (Ca <12, n = 17; Ca >13, n=2; P = 0. 17) or nephrolithiasis (Ca <12, n = 18; Ca >13, n = 12; P= 0. 18).

Conclusion: Severe hypercalcemia in PHPT reflects greater biochemical disease severity, yet histopathological and molecular profiles of parathyroid adenomas remain comparable across calcium levels. These findings suggest that hypercalcemia severity may stem from factors beyond tumor pathology, including functional variations in adenomas or host-specific influences. Further research is required to uncover mechanisms contributing to disease severity and their clinical implications.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches